← Eichor
Study identifier: NCT05894824 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Condition: Gastric Cancer · Gastroesophageal Junction (GEJ) Cancer  ·  Sponsor: Yonsei University

PhasePhase 1/Phase 2
Planned participants58
Who can joinAll sexes, 19 Years to no upper limit
Healthy volunteersNo

About this study

This is a Phase Ib/II study to identify the RP2D of T-DXd combination with Ram and to assess the safety and clinical efficacy of this combined treatment in advanced gastric cancer. The study will be conducted in two parts: Phase Ib dose escalation study to determine the MTD and RP2D of T-DXd combination and Ram, and Phase II to further evaluate the safety and tolerability of T-DXd combinations with Ram at the RP2D and determine anti-tumor activity.

This description comes directly from the study's public registry record.

Talk to the study team

SUN YOUNG RHA  ·  82-2-2228-8053  ·  rha7655@yuhs.ac

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Young RhaSeoul, Seoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05894824